清脆的
T细胞受体
基因组编辑
嵌合抗原受体
计算生物学
癌症免疫疗法
免疫疗法
生物
多路复用
基因组工程
T细胞
Cas9
转录激活物样效应核酸酶
癌症
基因
生物信息学
遗传学
免疫系统
作者
Nils Wellhausen,Sangya Agarwal,Philipp C. Rommel,Saar Gill,Carl H. June
标识
DOI:10.1016/j.coi.2021.10.008
摘要
T cells engineered to express transgenes such as chimeric antigen receptors (CAR) or modified T cell receptors (TCR) represent a new pillar of cancer therapy. Use of CRISPR/Cas gene–editing tools now allows even stronger and more precise control over the fate and function of engineered T cell therapies, including multiplex genome editing to facilitate use of off-the-shelf allogeneic T cells and novel approaches which have the potential to overcome some of the limitations of canonical Cas9-mediated DNA cleavage. This review summarizes the CRISPR/Cas techniques that have been used in preclinical research and outlines those that currently being tested in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI